Author:
Rodriguez-Abreu Delvys,Bosch-Barrera Joaquim,Gray Jhanelle E.,Ahn Myung-Ju,Johnson Melissa,Yu Xinwei,Mohammad Saad,Chen Xueying,Todd Trever,Kim Jongseok,Reck Martin
Reference17 articles.
1. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up;Hendriks;Ann Oncol,2023
2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for non-small cell lung cancer V.5.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed November 19, 2023.
3. Clinical pattern of failure after a durable response to immune checkpoint inhibitors in non-small cell lung cancer patients;Heo;Sci Rep,2021
4. Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses;Banta;Immunity,2022
5. Co-inhibition of TIGIT and PD-1/PD-L1 in cancer immunotherapy: mechanisms and clinical trials;Chu;Mol Cancer,2023